These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 28738453)

  • 61. [General hepatitis B vaccination--a challenge for public health in the year 2000].
    Raeber PA; Vaudaux B; Steffen R
    Soz Praventivmed; 1998; 43 Suppl 1():S3-4, S78. PubMed ID: 9833254
    [No Abstract]   [Full Text] [Related]  

  • 62. Foreword. Hepatitis B and the impact of immunization in China and the WHO Western Pacific Region.
    Yu W
    Vaccine; 2013 Dec; 31 Suppl 9():J2. PubMed ID: 24331016
    [No Abstract]   [Full Text] [Related]  

  • 63. Potential of specialist drug services to deliver hepatitis B vaccination.
    Morrison DS; Gilchrist G; Ahmed S
    Commun Dis Public Health; 2002 Dec; 5(4):321-3. PubMed ID: 12564250
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Legend of hepatitis B vaccination: the Taiwan experience.
    Chan CY; Lee SD; Lo KJ
    J Gastroenterol Hepatol; 2004 Feb; 19(2):121-6. PubMed ID: 14731119
    [TBL] [Abstract][Full Text] [Related]  

  • 65. What is the best hepatitis B vaccination strategy for South Africa?
    Karim SS
    S Afr Med J; 1998 Jun; 88(6):693-4. PubMed ID: 9687844
    [No Abstract]   [Full Text] [Related]  

  • 66. Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China.
    Cui F; Shen L; Li L; Wang H; Wang F; Bi S; Liu J; Zhang G; Wang F; Zheng H; Sun X; Miao N; Yin Z; Feng Z; Liang X; Wang Y
    Emerg Infect Dis; 2017 May; 23(5):765-772. PubMed ID: 28418296
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Hepatitis B remains a public health problem in France].
    Pol S
    Arch Pediatr; 2010 Mar; 17(3 Suppl):1-5. PubMed ID: 20304344
    [No Abstract]   [Full Text] [Related]  

  • 68. A mathematical model to estimate global hepatitis B disease burden and vaccination impact.
    Goldstein ST; Zhou F; Hadler SC; Bell BP; Mast EE; Margolis HS
    Int J Epidemiol; 2005 Dec; 34(6):1329-39. PubMed ID: 16249217
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [National hepatitis B vaccination closer to implementation, but not soon enough; recommendation from the Dutch Health Council].
    Brandt KH; Bruin A; van Hattum J; van Leeuwen-Gilbert P; de Man RA
    Ned Tijdschr Geneeskd; 2001 Aug; 145(33):1613. PubMed ID: 11534380
    [No Abstract]   [Full Text] [Related]  

  • 70. Economic evaluations of hepatitis B vaccination for developing countries.
    Tu HA; Woerdenbag HJ; Kane S; Riewpaiboon A; van Hulst M; Postma MJ
    Expert Rev Vaccines; 2009 Jul; 8(7):907-20. PubMed ID: 19538116
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Hepatitis B: the global problem, its prevention and future, and role of IMA.
    Roy S; Chakrabortti SC
    J Indian Med Assoc; 2000 Jul; 98(7):366. PubMed ID: 11143853
    [No Abstract]   [Full Text] [Related]  

  • 72. A global investment framework for the elimination of hepatitis B.
    Howell J; Pedrana A; Schroeder SE; Scott N; Aufegger L; Atun R; Baptista-Leite R; Hirnschall G; 't Hoen E; Hutchinson SJ; Lazarus JV; Olufunmilayo L; Peck R; Sharma M; Sohn AH; Thompson A; Thursz M; Wilson D; Hellard M
    J Hepatol; 2021 Mar; 74(3):535-549. PubMed ID: 32971137
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The Viral Hepatitis Prevention Board and earlier efforts at hepatitis B control.
    Wilde H
    Vaccine; 1996 Jun; 14(8):837-8. PubMed ID: 8817832
    [No Abstract]   [Full Text] [Related]  

  • 74. Time for universal hepatitis B screening for Australian adults.
    Allard NL; MacLachlan JH; Tran L; Yussf N; Cowie BC
    Med J Aust; 2021 Aug; 215(3):103-105.e1. PubMed ID: 34120343
    [No Abstract]   [Full Text] [Related]  

  • 75. Hepatitis B virus: is a cure possible?
    Zeisel MB; Baumert TF
    Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1129-30. PubMed ID: 27347775
    [No Abstract]   [Full Text] [Related]  

  • 76. Hepatitis and hepatitis immunisation.
    Feely M
    J R Soc Health; 1997 Feb; 117(1):41-6. PubMed ID: 9050293
    [No Abstract]   [Full Text] [Related]  

  • 77. Global hepatitis C elimination: an investment framework.
    Pedrana A; Howell J; Scott N; Schroeder S; Kuschel C; Lazarus JV; Atun R; Baptista-Leite R; 't Hoen E; Hutchinson SJ; Aufegger L; Peck R; Sohn AH; Swan T; Thursz M; Lesi O; Sharma M; Thwaites J; Wilson DP; Hellard M
    Lancet Gastroenterol Hepatol; 2020 Oct; 5(10):927-939. PubMed ID: 32730786
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Actively promoting full treatment regimen of hepatitis B in China for further modification of recommended Chinese guidelines for hepatitis B prevention and treatment].
    Wang DY
    Zhonghua Gan Zang Bing Za Zhi; 2023 Oct; 31(10):1101-1102. PubMed ID: 38016780
    [No Abstract]   [Full Text] [Related]  

  • 79. "Do-nothing" alternative and cost-minimization evaluations.
    Agarwal KS
    Indian J Gastroenterol; 2004; 23(5):194; author reply 194-5. PubMed ID: 15599014
    [No Abstract]   [Full Text] [Related]  

  • 80. A guideline for economic evaluations of vaccines and immunization programs in China.
    Fang H; Chen C; Fang Y; He X; Hou Z; Jiang M; Jiang Y; Li S; Liu Y; Sui B; Sun Q; Wu J; Xu T; Yang J; Yin Z; Ying X; Yuan B; Zheng H; Zheng Y
    Hum Vaccin Immunother; 2022 Nov; 18(6):2132802. PubMed ID: 36287462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.